InMed’s has discovered a diverse pipeline of drug candidates across a spectrum of diseases with high unmet medical needs, which are currently at various stages of clinical and preclinical development:

• INM-755, our lead product, is under development for the treatment of epidermolysis bullosa (“EB”), which is a severe genetic skin disorder. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in EB. According to various analyst reports, it is believed that there are an estimated 50,000 EB patients in North America, Europe and Japan;
• INM-088 is our product in preclinical development for the treatment of glaucoma, the second leading cause of blindness in the developed world.